Tnf Pharmaceuticals, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
PharmaCyte Biotech filed an amended Schedule 13D showing 74% beneficial ownership of Q/C Technologies via preferred stock, warrants, and recent $3M financing with anti-dilution protections.